LKT Labs

Biochemicals for Life Science Research

Dasatinib

Dasatinib

Product ID D023721
Cas No. 302962-49-8
Purity ≥99%
Product Unit SizeCostQuantityStock
25 mg $47.80 In stock
100 mg $88.60 In stock
250 mg $238.60 In stock
Bulk Quote

Quicklinks

Description

Dasatinib is an anticancer chemotherapeutic compound that inhibits Abl, PDGFR, ephrin receptors, Src, c-Kit, and other Src-family kinases (LCK, HCK, FYN, and others). Dasatinib is clinically used to treat chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL); in acute myelogenous leukemia (AML) cells, dasatinib induces myeloid differentiation and autophagy. Dasatinib also displays antiviral activity, preventing dengue virus infection through its inhibition of FYN kinase.

Product Info

Cas No.

302962-49-8
Purity

≥99%
Formula

C22H26ClN7O2S
Formula Wt.

488.01
IUPAC Name

N-(2-Chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl}amino)-1,3-thiazole-5-carboxamide
Synonym

BMS354825, BMS-354825, Sprycel

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

D023721 MSDS PDF
Info Sheet

D023721 Info Sheet PDF

References

Xie N, Zhong L, Liu L, et al. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. Biochem Pharmacol. 2014 May 1;89(1):74-85. PMID: 24607273.

de Wispelaere M, LaCroix AJ, Yang PL. The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol. 2013 Jul;87(13):7367-81. PMID: 23616652.

Montero JC, Seoane S, Ocaña A, et al. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011 Sep 1;17(17):5546-52. PMID: 21670084.

Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. PMID: 17154512.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • R183731

    Resiquimod

    Toll-like receptor 7/8 agonist

    ≥98%
  • A5302

    Anastrozole

    Aromatase inhibitor.

    ≥99%
  • C9670

    Cyromazine

    Triazine, melamine derivative, insect growth re...

    ≥98%
  • E9317

    Exemestane

    Aromatase inhibitor.

    ≥97%
  • B6935

    Brivudine

    Nucleoside (thymidine) analog; DNA chain termin...

    ≥98%
  • A5327

    Anagrelide

    Imidazoquinazoline; PDE3 inhibitor.

    ≥98%
  • M0173

    Mastoparan X

    Antimicrobial peptide found in bee and wasp ven...

    ≥95%
  • C0021

    Cafestol Acetate

    Diterpene found in brewed, unfiltered coffee; F...

    ≥98%
  • V0352

    Vandetanib

    RET, EGFR, VEGFR2 inhibitor.

    ≥98%
  • A7202

    AS-604850

    p110γ PI3K inhibitor.

    ≥98%
  • D1695

    Dexamethasone Phosphate Sodium

    Steroid; glucocorticoid agonist.

    ≥98%
  • G4479

    Glucagon (19-29), human

    Endogenous peptide hormone, glugagon fragment; ...

    ≥95%
  • B564086

    Boceprevir

    Inhibits HCV replication

    ≥98%
  • D1859

    2-Deoxy-D-glucose

    Glucose metabolism inhibitor, N-linked glycosyl...

    ≥99%
  • E0073

    Ebselen

    Synthetic glutathione peroxidase mimetic; yeast...

    ≥99%
  • D1869

    Deracoxib

    NSAID; COX-2 inhibitor.

    ≥99%
  • M4004

    MK-2461

    MET, FGFR, PDGFR inhibitor.

    ≥99%
  • L920000

    LX-2343

    Promotes Aβ clearance.

    ≥98%
  • A6058

    Apoptosis Activator 2

    Apoptosis inducing agent.

    ≥98%
  • D3575

    2,5-Di-tert-butyl-4-hydroxyanisole

    BHA derivative; potential Ca2+ ATPase inhibitor...

    ≥98%